Latest Exenatide Stories
National network of lawyers continues offer of complimentary consultations to consumers seeking compensation in lawsuits alleging links between diabetes medications Januvia, Byetta, Janumet and
- Smith takes-on innovative CXO role to optimize customer experiences and consistently deliver the best possible outcomes for patients, payors and providers - BOSTON, Feb.
Once-Weekly Dulaglutide Hits Primary Endpoint in Sixth Consecutive AWARD Trial INDIANAPOLIS, Feb.
The Firm is evaluating Byetta lawsuits on behalf of patients who allegedly developed pancreatic cancer, pancreatitis, or thyroid cancer due to their use of the Type 2 diabetes medication.
The Firm is investigating Byetta lawsuits on behalf of individuals who developed pancreatic cancer, thyroid cancer or pancreatitis, allegedly due to their use of the Type 2 diabetes medication.
The Firm is evaluating Byetta lawsuits and other legal claims on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis, and thyroid cancer due their use of incretin mimetic
JERUSALEM, Feb. 10, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
Company to Move Forward with FDA Phase 2b Multi-Center Trial JERUSALEM, Jan.
The Firm is currently evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, thyroid cancer, or pancreatitis due to their use of the Type 2 diabetes drugs.
JERUSALEM, January 27, 2014 /PRNewswire/ -- Oramed Pharmaceuticals Inc.
The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...
- totally perplexed and mixed up.